Effect of various absorption enhancers based on tight junctions on the intestinal absorption of forsythoside A in Shuang-Huang-Lian, application to its antivirus activity

Wei Zhou1,2,3, Xuan Xuan Zhu4, Ai Ling Yin1, Bao Chang Cai1, Hai Dan Wang4, Liuqing Di1,2,3, Jin Jun Shan5

1College of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, PR China, 2Jiangsu Engineering Research Center for Efficient Delivery System of TCM, Nanjing, PR China, 3Nanjing Engineering Research Center for Industrialization of Chinese Medicine Pellets, Nanjing, PR China, 4Department of Pharmacology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, PR China, 5First Medicine College, Nanjing University of Chinese Medicine, Nanjing, PR China

Submitted: 05-03-2013 Revised: 15-04-2013 Published: 07-02-2014

BACKGROUND: Forsythoside A (FTA), one of the main active ingredients in Shuang-Huang-Lian (SHL), possesses strong antibacterial, antioxidant and antiviral effects, and its pharmacological effects was higher than that of other ingredients, but the absolute bioavailability orally was approximately 0.72%, which was significantly low, influencing clinical efficacies of its oral preparations seriously.

MATERIALS AND METHODS: In vitro Caco-2 cell and in vivo pharmacokinetics study were simultaneously performed to investigate the effects of absorption enhancers based on tight junctions: sodium caprate and water-soluble chitosan on the intestinal absorption of FTA, and the eventual mucosal epithelial damage resulted from absorption enhancers was evaluated by MTT test and morphology observation, respectively. The pharmacological effects such as antivirus activity improvement by absorption enhancers were verified by MDCK damage inhibition rate after influenza virus propagation.

RESULTS: The observations from in vitro Caco-2 cell showed that the absorption of FTA in SHL could be improved by absorption enhancers. Meanwhile, the absorption enhancing effect of water-soluble chitosan may be almost saturable up to 0.0032% (w/v), and sodium caprate at concentrations up to 0.64 mg/mL was safe, but water-soluble chitosan at different concentrations was all safe for these cells. In pharmacokinetics study, water-soluble chitosan at dosage of 50 mg/kg improved the bioavailability of FTA in SHL to the greatest extent, and was safe for gastrointestinal from morphological observation. Besides, treatment with SHL with water-soluble chitosan at dosage of 50 mg/kg prevented MDCK damage after influenza virus propagation better significantly than that of control. CONCLUSION: Water-soluble chitosan at dosage of 50 mg/kg might be safe and effective absorption enhancer for improving the bioavailability of FTA and the antiviral activity in vitro in SHL.

KEY WORDS: Absorption enhancers, antivirus activity, Forsythoside A, Shuang–Huang–Lian, tight junction

INTRODUCTION

Compound prescriptions are the commonly used forms of traditional Chinese medicine, and oral administration is one of the most popular ways of compound prescriptions application. Shuang–Huang–Lian (SHL), a traditional Chinese formula containing Flos Lonicerae (FL), Radix Scutellariae (RS) and Fructus Forsythiae (FF), is shown to remove toxic heat and induce diaphoresis, and it has been widely used for treating acute upper respiratory tract infection, acute bronchitis, and light pneumonia. Its preparations, such as Shuang-Huang-Lian oral liquid, Shuang-Huang-Lian tablet, etc., are also extensively used for treating infectious diseases of the respiratory tract caused by virus or bacterial infection in clinical practice. However, it was reported that their efficacy were usually not satisfactory compared with that of injections, which becomes one of the most limited points in the development of compound preparations. The presumptions that...
whether the low bioavailability orally of SHL resulted in the poor efficacy or whether efficacy could be improved as the absorption of active ingredients in SHL was enhanced are all yet to be investigated.

Our previous studies have shown that the chemical ingredients in SHL included phenylethanoid glycosides, lignans, quinic acids, saponins, and flavonoids. Phillyrin (PR), chlorogenic acid (CA), and baicalin (BC), three representative active ingredients, are used officially as the marker compounds to characterize SHL preparations. It was found that PR played an important role in the effects of anti-inflammatory, antiviral, and anti-obesity etc., but Li et al., (2011) reported that the absorption of PR could be neither carried out in the gastrointestinal, nor improved by absorption enhancers such as SDS, bile salt, borneol and carbomer, etc., Besides, we also found that about 100% of the apically loaded PR was retained on the apical side from Caco-2 cell transport (unpublished). Conceptually, all compounds in the pharmaceutical product that are bioavailable in the systemic circulation can be considered as relevant active markers for pharmacological effect. Therefore, the real active ingredients of ligans in FF may be ligan aglycone, not lignan glycosides like PR. However, it was reported that forsythoside A (FTA), another pharmacological active ingredient of caffeyol glycosides in FF, showed strong antibacterial, antioxidant, and antiviral activities, but its absolute bioavailability in SHL orally was approximately 0.72%, significantly low. And it was found that FTA was survived positive correlation better than other ingredients like CA and BC between dose and effects of antibacterial and antiviral activities via pharmacokinetic/pharmacodynamic (PK/PD) combined with partial least squares (PLS) in SHL, and the antibacterial and antiviral activities effects were improved as the content of FTA in SHL was enhanced (unpublished). Besides, Tian et al., (2012) reported that the antibacterial effect against Staphylococcus aureus (G+) and Candida albicans of FTA was similar to that of BC, higher than that of CA and PR, and the antibacterial activity against Escherichia coli (G-) of FTA was higher than that of BC, CA, and PR, although the content of FTA in SHL was 500 μg/mL, significantly lower than that of BC in SHL. Therefore, FTA could be considered as one of the most important antibacterial and antivirus markers to control the quality of SHL preparations. How to improve the bioavailability of FTA would be related directly to the pharmacological efficacy improvement of SHL.

According to our previous study, it was shown that the intestinal absorption mechanism of FTA was mainly involved paracellular route transport governed by the tight junctions (TJs). And the modulation of the TJs by absorption enhancers would enhance the paracellular drug transport.

Therefore, the present study is to clarify the effects of various absorption enhancers based on tight junctions such as sodium caprate and water-soluble chitosan on the intestinal absorption of FTA in SHL via in vitro and in vivo models and to find suitable enhancers to improve the oral bioavailability of FTA.

**MATERIALS**

SHL extract was purchase from Harbin third pharmaceutical factory. To assure the homogeneity of the formulation and to prepare consistent hatched, the HPLC figureprint profile [Figure 1] of the SHL extract was analyzed, and the chromatographic analysis was described by Cao et al., (2006) and Zhou et al., (2011). All voucher specimens were deposited in our laboratory for future reference. FTA (98% pure) was purchased from Shanghai Nature Standard Co, Ltd. Ribavirin, phillyrin, chlorogenic acid, baicalin, and scutellarin (using as internal standard, IS) were purchased from National Institute for the Control of Pharmaceutical and Biological Products. Water-soluble chitosan (degree of deacetylation 91.7%, Molecular weight 73KDa) and sodium caprate were purchased from Moldepot Co, Ltd. Heparin sodium injection was purchased from Changzhou Qianhong Bio-pharma Co., Ltd. Methanol and acetonitrile (HPLC grade) were purchased from Merck, Germany, and water was purified by a Milli-Q water purification system (Millipore, Bedford, MA, USA). All other chemicals and reagents were of analytical grade.

**METHODS**

**In vitro Caco-2 cell model**

**Preparation of transport buffer**

Hank’s balanced salt solution (HBSS) was used as the transport buffer for the transport study in Caco-2 cell monolayer model. It was prepared by dissolving 9.5 g of commercial available HBSS powder in 1000 mL water. The pH value of the buffer was adjusted to pH 6.0 by 85% of phosphoric acid.

**Cell culture**

Caco-2 cells were cultured in high glucose Dulbecco’s modified eagle’s medium (DMEM, Gibco, Bethesda, MD) with 10% fetal bovine serum (Gibco), 1% nonessential amino acids (Gibco). Cells were cultured in a humidified atmosphere of 5% CO\textsubscript{2} at 37°C . After reaching 80% confluence, Caco-2 cells were harvested with 0.25% trypsin-EDTA solution and seeded in Transwell inserts (Nalge Nunc International. Roskilde, Denmark) in 6-well plates at a density of 1.0 × 10\textsuperscript{4} cells/cm\textsuperscript{2}. The protocols for cell culture in Transwell inserts were similar to those described previously.
Cytotoxicity tests of SHL with different absorption enhancers on Caco-2 cells

MTT (3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium bromide) test was used to estimate the potential cytotoxicities of the studied weeping forsythia extract with different absorption enhancers toward Caco-2 cells. The Caco-2 cells were seeded onto a 96-well plate at a seeding density of 5 × 10^4 cells/well in DMEM culture medium and cultured at 37°C for 24 h. Subsequently, the culture medium was replaced with SHL or absorption enhancers (combined with or without SHL) dissolved in HBSS (pH 6.0) at different studied concentrations (6.25, 12.5, 25, 50, 100 μM for FTA in SHL; 0.005, 0.01, 0.02, 0.04, 0.08, 0.16, 0.32, 0.64, 1.28 mg/mL for absorption enhancers with or without addition of 10 μM of FTA in SHL). Blank HBSS (pH 6.0) was employed as a negative control. Then the 96-well plate was incubated at 37°C for 24 h. Thereafter, 20 μL of 5 mg/mL MTT solution in HBSS was added to each well and the plate was incubated for another 4 h. The solutions in each well were then removed followed by dissolving the remained formazan crystals in the cells with 200 μL of DMSO. The absorbance of the mixture in the 96-well plate was then measured with a Kinetic microplate reader (Molecular Devices) at 570 nm. The cytotoxicity of each compound was calculated as the percentage of the absorbance relative to that of the negative control.

Effect of absorption enhancers on the absorption of FTA in SHL

Cell culture experiments were described previously. Briefly, after culture medium was aspirated, the cell monolayers were washed three times blank HBSS. The transepithelial
electrical resistance (TEER) values of cell monolayers were measured, which were more than 250 Ω × cm². The monolayers were incubated with the blank HBSS for 1 h with 37°C. Thereafter the incubation medium was aspirated. Afterwards, a solution containing the compound was loaded onto the apical side. Donor samples (400 μL) (Apical side) and receiver samples (400 μL) (Basolateral side) were taken at different times (typically 1 h), followed by the addition of 400 μL drug donor solution to the donor side (AP) and 400 μL of blank buffer to the receiver side (BL). The samples were taken at 0, 1, 2, 3, and 4h after incubation. At the end of the transport experiment, integrity of the monolayer was monitored by TEER value. The concentrations of the test compound were analyzed immediately using the UPLC-MS method described by our previous report.[14] The effects of absorption enhancers of different concentrations on the absorption of FTA in SHL were investigated.

**Rat in vivo pharmacokinetics study**

**Effect of absorption enhancers on the oral bioavailability of FTA in SHL**

Male Sprague–Dawley rats (~250 g) were obtained from Experimental Animal Center of Nanjing University of Chinese Medicine and kept in an environmentally controlled breeding room (temperature: 20 ± 2°C, humidity: 60 ± 5%) for 1 week. The animals were fasted for 12 h prior to drug administration.

The rats were randomly divided into nine groups with five rats in each group to receive various oral administrations. In Group 1, rats received SHL extract (equivalent to 10 mg/kg of FTA). In Group 2, rats received SHL extract (equivalent to 10 mg/kg of FTA) with the addition of 25 mg/kg sodium caprate orally. In Group 3, rats received SHL extract (equivalent to 10 mg/kg of FTA) with the addition of 50 mg/kg sodium caprate. In Group 4, rats received SHL extract (equivalent to 10 mg/kg of FTA) with the addition of 100 mg/kg sodium caprate. In Group 5, rats received SHL extract (equivalent to 10 mg/kg of FTA) with the addition of 150 mg/kg sodium caprate. In Group 6, rats received SHL extract (equivalent to 10 mg/kg of FTA) with the addition of 25 mg/kg water-soluble chitosan. In Group 7, rats received SHL extract (equivalent to 10 mg/kg of FTA) with the addition of 50 mg/kg water-soluble chitosan. In Group 8, rats received SHL extract (equivalent to 10 mg/kg of FTA) with the addition of 100 mg/kg water-soluble chitosan. In Group 9, rats received SHL extract (equivalent to 10 mg/kg of FTA) with the addition of 150 mg/kg water-soluble chitosan.

After dosing for 0, 5, 10, 15, 20, 30, 40, 55, 70, 100, 160, 250, 480 min, blood was collected from the pre-intubated catheter and put into tubes with heparin sodium injection (10 μL) and ascorbic acid (2 μg) at predetermined time points. Subsequently, plasma was prepared by centrifugation at 5000 rpm for 7 min and stored at -80°C for further analysis.

**Evaluation of gastrointestinal membrane toxicity caused by absorption enhancers via morphological observation**

**Preparation for microscopy**

Morphological observation of gastrointestinal tissues after the exposure of 8h was performed after oral administration of SHL with or without absorption enhancers by oral gavage as described in section 3.1.3.

**Microscopy**

On each glass slide two sections from each tissue were prepared and all slides were investigated in this study. All slides were coded to avoid the observer “bias” and were observed at a magnification of ×400 using a light microscope.

**Effect of SHL with or without water-soluble chitosan on influenza virus**

MDCK cells were grown as described[20] in Dulbecco’s Modified Eagle’s Medium (DMEM), supplemented with 10% Fetal Bovine Serum (FBS) and 1% Pen/Strep at 37°C in a humidified incubator. The media was changed two to three times per week. The influenza virus strain, A/PR8/34(H1N1) was purchased from Chinese Academy of Preventive Medicine. It was propagated in MDCK cells in the presence of 1 μg/mL of Trypsin_TPCK (Tosylamide Phenylethyl Chloromethyl Keton-treated Trypsin) (Sigma, USA) to create the working stock. During antiviral evaluations, media supplemented with FBS was sucked out and the cell washed with PBS and then it was treated as needed. The media supplemented with Trypsin_TPCK was added.

Serum after administration orally into SHL with or without water-soluble chitosan was added to the MDCK cells after the propagation with influenza virus. Ribavirin was used as positive control. The cells were incubated at 37°C for 48 hours before viability testing by measuring the conversion of MTT as describe in section 3.1.3.

**Calculation**

For Caco-2 monolayer model, the apparent permeability coefficient (P_app) was calculated as

\[ P_{app} = \left(\frac{dQ}{dt}\right)/\left[A \times C_0\right] \]

\[ dQ/dt (\mu g/S) \] was the flux rate, \( A \) was the effective surface area of the cell monolayer (4.2 cm²), and \( C_0 (\mu g/mL) \) was the initial drug concentration in the donor chamber. Inhibition rate = \[ (OD \ (drug)−OD \ (model))/(OD \ (control)−OD \ (model)) \].
Pharmacokinetic analysis
The peak concentrations (C\text{max}) and the time to reach the peak concentrations (T\text{max}) were determined directly from the plasma concentration–time profiles. The area under the curve (AUC) was calculated by the trapezoidal method from time zero to the final sampling. The absorption enhancement ratios of drugs with or without enhancers were calculated as

\[
\text{Absorption enhancement ratio} = \frac{\text{AUC with enhancer}}{\text{AUC control}}
\]

Statistical analysis
Statistical significance in the P\text{app} value and pharmacokinetic parameters was estimated by the analysis of variance (Student t-test) or one-way ANOVA. A P value of less than 0.05 was considered to be significantly different. All data were expressed as mean ± SD.

RESULTS

In vitro Caco-2 monolayer model
Cytotoxicity tests of SHL with different absorption enhancers on Caco-2 cells
Caco-2 cells were exposed to various concentrations of absorption enhancers (0.005, 0.01, 0.02, 0.04, 0.08, 0.16, 0.32, 0.64, 1.28 mg/mL) with addition of SHL for 24 h. It was shown that sodium caprate at concentrations up to 0.64 mg/mL was safe for the Caco-2 cells, but water-soluble chitosan at different concentrations was all safe for these cells.

Effect of different absorption enhancers on the P\text{app} value of FTA in SHL in the apical-to-basolateral (AP-BL) direction from in vitro Caco-2 monolayer model
As shown in Figure 2, the P\text{app} values increased significantly to 106% (4.93 ± 0.33)×10^{-6} cm/s, 187% (8.69 ± 0.36)×10^{-6} cm/s and 155% (7.23 ± 1.07)×10^{-6} cm/s following exposure of the Caco-2 cells to 10, 32, and 250 μg/mL of the water-soluble chitosan. Additionally, the P\text{app} values also increased significantly to 127% (5.90 ± 0.74)×10^{-6} cm/s, 156% (7.25 ± 0.79)×10^{-6} cm/s and 203% (9.44 ± 0.59)×10^{-6} cm/s following exposure of the Caco-2 cells to 10, 32 and 80 μg/mL of the sodium caprate. The results indicated that the absorption of FTA in SHL can be improved by absorption enhancers based on tight junctions. Meanwhile, the absorption enhancing effect of water-soluble chitosan may be almost saturable up to 0.0032% (w/v).

In vivo pharmacokinetics study
Effects of absorption enhancers on the bioavailability of FTA in SHL
As shown in Table 1 and Figure 3, 150 mg/kg sodium caprate and 25 mg/kg water-soluble chitosan did not improve the absorption of FTA so much. The rank order of the absorption-enhancing ability was 150 mg/kg sodium caprate >50 mg/kg water-soluble chitosan >100 mg/kg sodium caprate >50 mg/kg sodium caprate >150 mg/kg water-soluble chitosan >25 mg/kg sodium caprate ≥100 mg/kg water-soluble chitosan ≥25 mg/kg water-soluble chitosan. However, sodium caprate at the dosage of 150 mg/kg might result in the serious intestinal damage as described below. Therefore, these findings indicated that 50 mg/kg water-soluble chitosan, not 150 mg/kg sodium caprate would be the promising enhancer for improving the bioavailability of FTA in rats.

Effect of absorption enhancers on the gastrointestinal membrane toxicity
Morphological observation of the intestinal mucosa after administration orally SHL and absorption enhancers were shown in Figure 4 (A1-A11: Stomach, B1-B11: Jejunum, C1-C11: Colon). The results clearly indicated that 25, 50, 100 mg/kg sodium caprate and 25, 50, 100, 150 mg/kg water-soluble chitosan did not cause any significant change in the morphology of the gastrointestinal membrane, although we found that above 100 mg/kg sodium caprate could cause mucosal damage.

Effect of SHL with or without water-soluble chitosan at the dosage of 50 mg/kg on influenza virus
As shown in Figure 5, the antivirus model was built successfully, and the inhibition rate of water-soluble chitosan group was no significant compared with that of PBS group, although there was a remarkable increase in inhibition rate value after administrating orally 20 mg/kg ribavirin as a positive control. However, the difference of antivirus activity between SHL with or without water-soluble chitosan was significant from Figure 5. The inhibition rate of SHL
with water-soluble chitosan at dosage of 50 mg/kg was higher than that of without water-soluble chitosan, which indicated that the pharmacological effects such as antivirus effect of SHL can be significantly improved by addition of water-soluble chitosan.

**DISCUSSION**

In the present study, it was reported by Illum *et al.*, (1994)\[^{21}\] that the mechanism of absorption enhancement of water-soluble chitosan was a combination of mucoadhesion and a loosening effect on the tension of the tight junctions through ionic interactions with negatively charged groups of glycocalix. Lindmark *et al.*, (1998)\[^{15}\] proposed that the mechanism of absorption enhancing effect of sodium caprate was proposed to be an effect on tight junctions through PLC-dependent IP3/DAG pathways. Furthermore, we found that the absorption enhancing effect of sodium caprate and water-soluble chitosan for improving the intestinal absorption of FTA was affected by their concentrations, and the absorption of FTA increased as the concentration of sodium caprate was enhanced by *in-vitro* and *in-vivo* models [Figures 2, and 3a and Table 1]. Besides, a maximal absorption enhancing effect of water-soluble chitosan was observed at a dosage of 50 mg/kg, not higher doses *in vivo* model, and the absorption enhancing effect may be almost saturable up to 0.0032% (w/v) *in vitro* model [Figures 2 and 3b and Table 1]. Gao *et al.*, (2008)\[^{17}\] reported that the absorption enhancing effect of chitosan hexamer for FD4 was dependent on its concentration, but its absorption enhancing effect was almost saturable up to 0.5% (w/v). Therefore, our present result is consistent with the previous report and chitosan has some optimal concentrations to show the greatest absorption enhancing effects for improving the intestinal absorption of FTA in SHL, although the type of chitosan was different. The reasons that the greatest absorption enhancing effects of chitosan was dependent on some optimal concentrations might be illustrated by the previous report that the chitosan of low concentration cannot enhance the absorption of drugs because of loss of interactions with negatively charged groups of
glycocalix, but chitosan of high concentration decreased the absorption rate of drugs owning to its high viscosity.\cite{22}

When absorption enhancers are applied in clinical practice, their potential local toxicity should be considered. We observed the morphological changes of gastrointestinal mucosa in the presence or absence of absorption enhancers. It can be found from Figure 4 that there was no significant damage in the gastro and colon tissues with sodium caprate at different dosages, but there was significant damage in the small intestine in the presence of 150 mg/kg sodium caprate, which was consistent with the previous report shown by Motlekar et al., (2005)\cite{23} that above 100 mg/kg sodium caprate

### Table 1: Effects of absorption enhancers on the absorption of FTA in SHL (10 mg/kg) by in vivo pharmacokinetics study

| Enhancement Type | C<sub>max</sub> (ng/mL) | T<sub>max</sub> (min) | AUC<sub>0-600 min</sub> (ng min/mL) | Enhancement ratio |
|------------------|--------------------------|----------------------|-----------------------------------|-------------------|
| Control          | 32.9±15.5                | 73.3±20.8            | 9047.5±82.7                       | -                 |
| Sodium caprate   |                          |                      |                                   |                   |
| 150 mg/kg        | 125.7±39.3               | 16.7±11.5            | 26028±6649.8**                    | 2.88±0.73         |
| 100 mg/kg        | 90.8±8.6                 | 20.0±14.1            | 16684.5±2372.3**                  | 1.84±0.26         |
| 50 mg/kg         | 84.1±29.4                | 10.0±0.0             | 16366±1830*                       | 1.81±0.59         |
| 25 mg/kg         | 47.7±19.8                | 55±0.0               | 11761.8±2486.2**                  | 1.35±0.23         |
| Water soluble Chitosan |                  |                      |                                   |                   |
| 150 mg/kg        | 55.9±5.9                 | 55±0.0               | 14196.7±368.6*                    | 1.56±0.04         |
| 100 mg/kg        | 55.3±37.4                | 10±0.0               | 12586±775.7**                     | 1.39±0.09         |
| 50 mg/kg         | 88.4±0.8                 | 10±0.0               | 16955.7±2524.6**                  | 2.03±0.28         |
| 25 mg/kg         | 40.7±17.1                | 55±0.0               | 11942.7±601.0*                    | 1.32±0.06         |

\(* P<0.05, \quad \ast \ast \ P<0.01, \quad \text{n.s.) no significant difference, compared with the control (mean±S.D., n=5)\)
could cause mucosal damage. However, there was no significant change in the presence of water-soluble chitosan at different dosages.

The present study also demonstrated that the absorption of FTA in SHL can be improved to the greatest extent, and was safe for gastrointestinal by sodium caprate at dosage of 100 mg/kg and water-soluble chitosan at dosage of 50 mg/kg, respectively. However, as shown in Table 1, we found that enhancing effect of water-soluble chitosan at dosage of 50 mg/kg was better than that of sodium caprate at dosage of 100 mg/kg. Meanwhile, Gao et al., (2008)[15] reported the effect of chitosan oligomers on the absorption of FD4, and found that the bioavailability of FD4 can be increased by 2.5-fold by chitosan hexamer from in situ loop method. Thanou et al., (2001;2007)[24,25] showed the effect of low viscosity grade Mono-N-Carboxymethyl Chitosan (LMCC), high low viscosity grade N-sulfonato-N, O-carboxymethyl-Ichitosan (SNOCC-60) on the absorption of low molecular weight heparin (LMWH), and found that the AUC value can be increased by 7 and 18-fold, respectively by intraduodenally administration. Therefore, chitosan derivatives as absorption enhancers need to be further investigated in order to improve the pharmacological effects of SHL formulation better. Besides, Because of complexity of Chinese medicine, not only FTA, but also other ingredients like CA, caffeic acid,[29] etc., in SHL could also be affected by the absorption enhancers based on tight junctions, although their pharmacological effects were weaker than that of FTA. Therefore, in order to control the quality of preparation better, the study involved in the CA, caffeic acid etc., improved by absorption enhancers based on TJs need to be also further investigated.

REFERENCES

1. Lv M.B. Progresses in the clinical application of Shuang-Huang-Lian preparations. Chin J Hosp Pharm 1997;17:81-2.
2. Hua J, Ye M, Guo H, Yang M, Wang BR, Guo DA. Analysis of multiple constituents in a Chinese herbal preparation Shuang-Huang-Lian oral liquid by HPLC-DAD-ESI-MS*. J Pharm Biomed Anal 2007;28:430-8.
3. Chinese Pharmacopoeia Commission, 2010. The Pharmacopoeia of the People’s Republic of China Version (2010). Beijing: Chinese Medical Science Technology Press; 2010. 611 pp. Diaz Lanza AM, Abad Martinez MJ, Fernandez Matellano L, Recuero Carretero C, Villaescusa Castillo L, Silvan Sen AM, et al. Lignan and phenylpropanoid glycosides from Philyreia latifolia and their in vitro anti-inflammatory activity. Planta Med 2001;67:219-23.
4. Shi Y, Shi RB, Liu B, Lu YR, Du LJ. Isolation and elucidation of chemical constituents with antiviral action from yinqiaoas on influenza virus. Zhongguo Zhong Yao Za Zhi 2003;28:43-7.
5. Zhao Y, Li F, Yang J, An X, Zhou M. Effect of phillyrin on the anti-obesity in nutritive obesity mice. Zhong Yao Cai 2005;28:123-4.
6. Li YX, Peng C, Ye LH, Zhang RQ, Jiang XH. Investigation on the absorption of phillyrin and forsythiaside in rat digestive tract. Eur J Drug Metab Pharmacokinet 2011;36:79-85.
7. Wang L, Wang ZJ, Wo SK, Lau CB, Chen X, Huang M, et al. A bio-activity guided in vivo pharmacokinetic method to improve the quality control of Chinese medicines, application to Si Wu Tang. Int J Pharm 2011;406:99-105.
8. Zhang LW, Zhao CG, Yang P. Study on the antioxidant activity and structure-activity relationship of Forsythia. Chin Pharm J 2003;38:334-6.
9. Qu H, Zhang Y, Wang Y, Li B, Sun W. Antioxidant and antibacterial activity of two compounds (forsythiaside and forsythin) isolated from Forsythia suspense. J Pharm Pharmacol 2008;60:261-7.
10. Ma YY, Zhang ZW, Li HW, Sun JH, Xu CY, Wu GJ. Effects of forsythoside A on the Expression of IFN-α and Mx1. Sci Agr Sin 2010;34:323-47.
11. Ye JX, Wei W, Quan LH, Liu CY, Chang Q, Liao YH. An LC–MS/MS method for the simultaneous determination of chlorogenic acid, forsythiaside A and baicalin in rat plasma and its application to pharmacokinetic study of Shuang-huang-lian in rats. J Pharm Biomed Anal 2010;52:625-30.
12. Tian L, Zhou W, Di LQ, Yu JH, Dan JJ, Bi XL, et al. Study on in vitro antibacterial effects correlation between the main active components in Shuang-Huang-Lian oral liquid. J Nanjing Univ Tradit Chin Med 2012;28:89-91.
13. Zhou W, Di LQ, Wang J, Shan JJ, Liu SJ, Ju WZ, et al. Intestinal absorption of forsythoside A in in situ single-pass intestinal perfusion and in vitro Caco-2 cell models. Acta Pharmacol Sin 2012;33:1069-79.
14. Lindmark T, Kimura Y, Artursson P. Absorption enhancement through intracellular regulation of tight junction permeability by medium chain fatty acids in Caco-2 cells. J Pharmacol Exp Ther 1998;284:362-9.
15. Bernkop-Schnürch A. Chitosan and its derivatives: Potential excipients for peroral peptide delivery systems. Int J Pharm 2000;194:1-13.
16. Gao Y, He L, Katsumi H, Sakane T, Fuita T, Yamamoto A. Improvement of intestinal absorption of insulin and water-soluble macromolecular compounds by chitosan oligomers in rats. Int J Pharm 2008;359:70-8.
17. Zhou W, Di LQ, Bi XL, Zhao XL. Determination of baicalin, chlorogenic acid, forsythin and forsythoside A in Shuang-Huang-Lian oral liquid by dual-wavelength HPLC. Chin J Tradit Chin Med Pharm 2011;26:2111-3.
18. Jin X, Zhang ZH, Sun E, Tan XB, Zhuu FX, Li SL, et al. Preparation of icariside α – phospholipids complex and its absorption across Caco-2 cell monolayers. Pharmacazie 2012;67:293-8.
19. Mehrbod P, Motamed N, Tabatabaiai M, Soleimani ER, Amini E, Shahidi M, et al. In vitro antiviral effect of “Nanosilver” on influenza virus. Drug 2009;17:88-93.
20. Illum L, Farraj NF, Davis SS. Chitosan as a novel nasal delivery system for peptide drugs. Pharm Res 1994;11:1186-9.
21. Li YH, Zhang M, Wang JC, Zhang S, Liu JR, Zhang Q. Effects of absorption enhancers on intestinal absorption of lumbrokinase. Yao Xue Xue Bao 2006;41:939-44.
22. Motekar NA, Srivenugopal KS, Wachtel MS, Youan BB. Oral delivery of low-molecular-weight heparin using sodium caprate as absorption enhancer reacher therapeutic levels. J Drug Target 2005;13:573-83.
23. Thanou M, Nihot MT, Jansen M, Verhoef JC, Junginger HE. Mono-N-Carboxymethyl Chitosan (MCC), a polyampholytic chitosan derivative, enhances the intestinal absorption of low molecular weight heparin across intestinal epithelia in vitro and in vivo. J Pharm Sci 2001;90:38-46.
24. Thanou M, Henderson S, Kydonieus A, Elson C. N-sulfonato-N, O-carboxymethylchitosan: A novel polymeric absorption enhancer for the oral delivery of macromolecular. J Control Release 2007;117:171-8.

25. Konishi Y, Kobayashi S. Transepithelial transport of chlorohenic acid, caffeic acid, and their colonic metabolites in intestinal Caco-2 cell monolayers. J Agric Food Chem 2004;52:2518-26.

Cite this article as: Zhou W, Zhu XX, Yin AL, Cai BC, Wang HD, Di L, et al. Effect of various absorption enhancers based on tight junctions on the intestinal absorption of forsythoside A in Shuang-Huang-Lian, application to its antivirus activity. Phcog Mag 2014;10:9-17.

Source of Support: Supported financially by “Qing Lan” Project from Jiangsu Provincial Technology Innovation Team Support Scheme, the priority Academic Program Development of Jiangsu Higher Education Institution (No ysxk-2010) and 2012 program sponsored for scientific innovation research of college graduate in Jiangsu province (623).

Conflict of Interest: None declared.
